Conditions: Stage III Non-small Cell Lung Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 106
Healthy volunteers: no

Brief summary:
Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and pemetrexed) with concurrent radiotherapy.

Detailed description:

Arms:
arm 1: Chemoradiotherapy

Interventions: intervention 1: Chemotherapy intervention 2: ERBITUX intervention 3: Radiotherapy
Intervention descriptions: intervention 1: Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles) intervention 2: The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes intervention 3: 66 Gy (2 Gy by fraction, 5 fractions by week)

Protocol document: